跳至主要内容
临床试验/NCT01844635
NCT01844635Unknown3 期

A Prospective Randomized Multicenter Study Comparing Different Dosages of Rabbit Antithymocyte Globulin (Thymoglobuline) in Patients With Severe Aplastic Anemia

Nagoya University1 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
320
试验地点
1
主要终点
Hematologic response (complete response (CR) or partial response (PR)) in patients with immunosuppressive therapy (IST) on day 180 after the start of IST.

研究概览

简要总结

The objective of this study is to evaluate the feasibility and effectiveness of immunosuppressive therapy (IST) using rabbit anti-thymocyte globulin (ATG) (Thymoglobuline, Genzyme) for patients with very severe aplastic anemia (VSAA) and severe aplastic anemia (SAA) as a primary therapy. The primary endpoint is the response rate (complete response (CR) + partial response (PR)) at day 180 after the start of IST. Secondary endpoints include evaluation of the presence and frequency of Epstein-Barr virus (EBV)-reactivation and EBV-associated lymphoproliferative disorder (EBV-LPD), Cytomegalovirus(CMV)-reactivation and CMV associated diseases, the response rate (CR+PR) on Day 360 after the start of IST, relapse rate and overall survival.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 69 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acquired aplastic anemia
  • Age: younger than 70 years old
  • Severity: SAA, VSAA.
  • Interval between diagnosis and registration <6 months.
  • Written informed consent from the caretakers and/or whenever possible consent from the patient.

排除标准

  • 未提供

研究组 & 干预措施

2.5 mg/kg/day of Thymoglobulin for 5 days

Experimental

2.5 mg/kg/day of Thymoglobulin for 5 days

干预措施: Thymoglobulin (Drug)

3.5 mg/kg/day of Thymoglobulin for 5 days

Active Comparator

3.5 mg/kg/day of Thymoglobulin for 5 days

干预措施: Thymoglobulin (Drug)

结局指标

主要结局

Hematologic response (complete response (CR) or partial response (PR)) in patients with immunosuppressive therapy (IST) on day 180 after the start of IST.

时间窗: day 180 after the start of IST

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hideki Muramatsu

Assistant Professor

Nagoya University

研究点 (1)

Loading locations...

相似试验

Randomised Study Comparing Different Dosages of... | 临床试验